The largest database of trusted experimental protocols

10 protocols using centrisart tube

1

Determining Entrapment Efficiency of Drug Formulations

Check if the same lab product or an alternative is used in the 5 most similar protocols
The entrapment efficiency was determined by the ultrafiltration method [40 (link)] using a Centrisart tube with a molecular weight cut-off of 10 kDa (Sartorius, Gottingen, Germany). Centrifugation was performed on the device containing 2 mL of the sample in the donor chamber for 30 min at 6000 rpm to separate the unloaded DTX or CCM in the aqueous phase into the inner floater tube. The drug solution in both the recovery and donor chambers was collected and quantified using the HPLC method as outlined in our previous report [30 (link)]. The following equation was used to calculate the percentage of drug that was entrapped.
Entrapment efficiency (%)=Winitial  Wobtained Winitial × 100 
where “ Winitial ” is the amount of drug loaded in the formulation, while “Wobtained” is the amount of unloaded drug in the aqueous phase of the formulation.
+ Open protocol
+ Expand
2

Metformin Hydrochloride Entrapment in Lipid Vesicles

Check if the same lab product or an alternative is used in the 5 most similar protocols
The average sizes of the primary emulsification product (W1/O) and also the lipid vesicles formed were determined using a dynamic light scattering machine (DLS, Zetasizer Nano ZS, Malvern Instruments, Worcester, UK). The intensity versus size distributions of the particles were presented. The entrapment yield (EY) of metformin hydrochloride in the prepared lipid vesicles was determined using UV–Vis spectrophotometric detection of the drug. Equal volumes of methanol and lipid vesicle suspension were mixed together in a vial, a treatment that leads to the destruction of the vesicle membranes, releasing their contents into the medium. The solution was then subjected to centrifugal filtration for 25 min at 4000 rpm using a Centrisart tube (Sartorius, Germany) with 10 kDa molecular weight cut-off. Analysis of the clear permeate obtained was performed using UV–Vis spectrophotometer (Jenway, model 6504, UK) at 236 nm to give total concentration (Ctotal) of the free drug and the entrapped ones. For the concentration of the free/unentrapped drug (Cout), a mixture of the vesicle suspension and phosphate buffer was made and subjected to the above filtration condition. The lipid vesicles were precipitated and the permeate analyzed at 236 nm using a UV–Vis spectrophotometer.
The entrapment yield, EY, was therefore calculated using the formula: Entrapment yield (%) = CtotalCoutCtotal×100
+ Open protocol
+ Expand
3

Encapsulation Efficiency of CLN

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ultrafiltration method using the Centrisart tube (molecular weight cutoff of 10,000 Da; Sartorius AG, Göttingen, Germany) was used to determine the encapsulation efficiency of CLN.13 Next, 2.0 mL of sample was placed in the outer chamber and centrifuged at 3,500 rpm for 15 min. The aqueous phase was collected from the floater that was inserted into the tube after centrifugation. The resultant aqueous phase was analyzed using HPLC conditions, as previously mentioned in the “HPLC analysis” section, to estimate the amount of drug (cefuroxime). Cefuroxime concentration entrapped in the emulsion system was calculated from the difference between the total and the free drug concentrations in the ultrafiltrate.
+ Open protocol
+ Expand
4

Encapsulation Efficiency of CS-Coated Metronidazole SLNs

Check if the same lab product or an alternative is used in the 5 most similar protocols
The % DL and EE of CS-coated MTZ-loaded SLN were evaluated using ultrafiltration with Centrisart® tubes (Sartorius AG, Göttingen, Germany) fitted with a cellulose triacetate membrane of 20 kDa molecular weight cut-off. Prior to analysis, approximately 2.0 mL of the SLN formulation was transferred into the outer chamber of the Centrisart® tube, after which the tubes were centrifuged for 30 min at a speed of 2500 rpm using a model HN-SII Thermo IEC bench-top centrifuge (Damon, MA, USA) to separate the aqueous phase that contained free MTZ. A solution containing free MTZ was transferred into a 10 mL A-grade volumetric flask and increased in volume with HPLC-grade methanol (MeOH) (Microsep®, Gqeberha, South Africa) prior to quantitation using a validated RP-HPLC method [39 ]. The % DL and EE were calculated using Equations 2 [40 (link)] and 3 [41 (link)].
EE=total amount of MTZamount of free MTZtotal amount of MTZ×100%
DL=total amount of MTZamount of free MTZtotal amount oflipid phase×100%
+ Open protocol
+ Expand
5

Formulation and Characterization of Cefuroxime Nanocarriers

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cefuroxime, (6R,7R)-3-{[(aminocarbonyl)oxy]methyl}-7-{[(2Z)-2-(2-furyl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, was purchased from Euroasias Chemical Private Limited (Mumbai, India). Safflower seed oil, soybean oil, sunflower oil, pine nut oil, olive oil, Cremophor EL, and sodium oleate were purchased from Sigma-Aldrich Co. (St Louis, MO, USA). Lecithin Lipoid S75 was also purchased from Lipoid GmbH (Ludwigshafen, Germany); Tween 80 (polyoxyethylene sorbitan monooleate) was purchased from Merck (Hohenbrunn, Germany), and glycerol was purchased from J.T. Baker (Phillipsburg, NJ, USA). All the used oils and surfactants were analytically graded materials. Acetonitrile (high-performance liquid chromatographic [HPLC] grade, 99.9% purity) was purchased from J.T. Baker. Sodium hydroxide (analytical grade) was purchased from Merck Millipore (Billerica, MA, USA). Water was deionized and Milli-Q filtered. Centrisart tubes and dialysis membranes were from Sartorius AG (Göttingen, Germany). All other chemicals and reagents were of analytical or HPLC grade.
+ Open protocol
+ Expand
6

Nanoparticle Encapsulation Efficiency Determination

Check if the same lab product or an alternative is used in the 5 most similar protocols
EE was determined by measuring the concentration of the free drug (unentrapped) in the external aqueous phase based on an earlier reported method [26 (link)]. The aqueous medium was separated by ultra-filtration using centrisart tubes (Sartorius, Goettingen, Germany), which consisted of a filter membrane (Mwt. cut off 20 KDa) at the base of the sample recovery chamber. About 2.5 mL of the SLNs were placed in the outer chamber, and the sample recovery chamber was placed on top of the sample and centrifuged at 15,000 rpm for 15 min. The SLNs, along with the encapsulated drug, remained in the outer chamber and the aqueous phase moved into the sample recovery chamber through the filter membrane. The amount of IR in the aqueous phase was estimated using the above described HPLC method. The EE of the IR-LNFs were calculated using the following equation: %EE=[Amount of IR in assayAmount of the unentrapped IRAmount of weighed IR]×100
+ Open protocol
+ Expand
7

SHH Peptide Encapsulation Efficiency in Nanoliposomes

Check if the same lab product or an alternative is used in the 5 most similar protocols
The encapsulation efficiency (EE) of the SHH peptides in the nanoliposomes was determined using the indirect method described by da Rosa Zavareze et al. [31 (link)], with some modifications. A quantity of 25 μL of each nanoliposome (Lip lecithin 2% 1 kDa or 10 kDa 10 mg/mL) was diluted in a volume of 975 μL of ultrapure water and then placed in Centrisart® tubes with 100 kDa exclusion size (Sartorius®, Goettingen, Germany), which can retain the nanoliposomes and let the unencapsulated SHH pass. The parameters of the centrifugation were as follows: Beckman Coulter® Rotor J-20 (Beckman Coulter, Brea, CA, USA) at 8000 rpm for 20 min at 20 °C. The quantity of non-encapsulated proteins was measured using the bicinchoninic acid (BCA) acid kit and expressed in μg eq. BSA/mL. The encapsulation efficiencies were estimated as follows: Encapsulation Efficiency %=100AB×100
where A is the equivalent in µg BSA/mL of the non-encapsulated SHH; B is the equivalent in µg BSA/mL of the different SHH fractions, SHH2 and SHH3.
+ Open protocol
+ Expand
8

Invasin-Functionalized Liposome Conjugation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 15

Invasin conjugation to the liposomal surface was based on covalent immobilization of the N-terminal of the protein to the carboxylic groups on the liposomal surface which were first activated using EDC/NHS (EDC: N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (Sigma Aldrich, Steinheim, Germany; NHS: N-hydroxysuccinimide, 99% (Carbolution Chemical GmbH, Saarbrücken, Germany). A volume of 300 μl of 48 mM EDC/19 mM NHS in 100 mM MES buffer (pH 6) was incubated overnight with a 2 ml liposomal dispersion with shaking at room temperature, centrifuged (Rotina 420R; Hettich Zentrifugen, Tuttlingen, Germany) in Centrisart® tubes 300,000 MWCO (Sartorius, Goettingen, Germany) at 3270 g, 4° C. for 30 min to remove excess free reagent followed by three successive washing steps during which the MES buffer was gradually exchanged with PBS, pH 7.4. The volume was then completed to 2.5 ml with PBS. 300 μl of 1 mg/ml invasin in PBS was added and coating process was continued overnight in ice bath with shaking. This was followed by centrifugation and washing steps in Centrisart® tubes 300,000 MWCO to remove unbound invasin. Covalent attachment of BSA (Sigma Aldrich, Steinheim, Germany) on liposomes followed the same protocol and served as controls for cell adhesion experiments.

+ Open protocol
+ Expand
9

Determining Nisoldipine Entrapment Efficiency

Check if the same lab product or an alternative is used in the 5 most similar protocols
About 0.2mL of the NSPSLN/NSPNLCs formulation was diluted to 10mL with chloroform and methanol mixture (1:1) and then further dilutions were made with the mixture of above solvents. The diluted samples were estimated by UV-visible spectrophotometer at λ max 238nm for the amount of Nisoldipine present. Entrapment efficiency of the system was determined by measuring the concentration of free drug (unentrapped) in aqueous medium as reported previously by Venkateshwarlu and Manjunath, 2004. 12 The aqueous medium was separated by ultracentrifugation using centrisart tubes (Sartorius, USA) which consist of filter membrane (M.Wt.cut off 20,000 Da) at the base of the sample recovery chamber. About 1mL of the undiluted sample of NSPSLN/NSPNLCs formulation was placed in the outer chamber and sample recovery chamber placed on top of the sample and centrifuged at 12,000 rpm for 15 min. The SLN/NLCs along with the encapsulated drug remain in the outer chamber and aqueous phase moves into the sample recovery chamber through the filter membrane. The amount of the NSP in the aqueous phase was estimated by UV-spectrophotometer at λ max 238nm. The entrapment efficiency of Nisoldipine SLN/NLC was calculated using the formula:
+ Open protocol
+ Expand
10

Encapsulation Efficiency of Nanoparticles

Check if the same lab product or an alternative is used in the 5 most similar protocols
EE was determined by measuring the concentration of the unentrapped (free drug) in the aqueous medium based on an earlier reported experiment 35 . The aqueous medium was separated by ultra-filtration using centrisart tubes (Sartorius, Goettingen, Germany), which consisted of a filter membrane (MWt. cut off 20 kDa) at the base of the sample recovery chamber. A measured volume of the formulations (2.5 mL) was taken and placed in the outer chamber, and the sample recovery chamber was placed on top of the sample and centrifuged (Remi, India) for 15 mins at 15000 rpm. The filtrate was collected and analyzed for free RP by HPLC after proper dilution with ethanol. The EE of RP in nanoparticles was calculated based on the following formula:
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!